Access new resources for advanced therapy development, from candidate identification through market authorization.


This white paper delves into the key decisions required in the development of cell and gene therapies and explores their profound impact on subsequent stages of the therapy’s life cycle. From early decisions on indication prioritization, engagement with patients and patient advocacy groups, manufacturing and contract development and manufacturing organization (CDMO) selection, to long term follow up design, each decision bears consequences that ripple across regulatory approval, commercial viability, market access, and further iterations of therapy development. By mapping these decisions at the earliest possible point, stakeholders can navigate the complex landscape of cell and gene therapy development with enhanced precision and insight.
Access new resources for advanced therapy development, from candidate identification through market authorization.
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.